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To	determine	antimicrobial	drug	resistance	mechanisms	of	
Shigella spp.,	we	analyzed	344	 isolates	collected	 in	Swit-
zerland	during	2004–2014.	Overall,	78.5%	of	isolates	were	
multidrug	resistant;	10.5%	were	ciprofloxacin	resistant;	and	
2%	harbored	mph(A), a plasmid-mediated gene that con-
fers	 reduced	 susceptibility	 to	 azithromycin,	 a	 last-resort	 
antimicrobial agent for shigellosis.
Shigella spp. are the etiologic agents of acute invasive intestinal infections clinically manifested by watery 
or bloody diarrhea. Shigellosis represents a major burden 
of disease, especially in developing countries, and is esti-
mated to affect at least 80 million persons, predominantly 
children, each year (1). Disease may be caused by any of 
the 4 Shigella species: S. dysenteriae, S. flexneri, S. boy-
dii, and S. sonnei. In industrialized countries, the most 
common species is S. sonnei, but this species is spread-
ing intercontinentally to developing countries as a single, 
rapidly evolving lineage (2). By contrast, in developing 
countries, the predominant species is S. flexneri, which 
is characterized by long-term persistence of sublineages 
in shigellosis-endemic regions with inadequate hygienic 
conditions and unsafe water supplies (3). More rarely 
isolated are S. dysenteriae, responsible for large epidem-
ics in the past, and S. boydii (4). Although shigellosis is 
principally a self-limiting disease, the World Health Orga-
nization guidelines recommend antimicrobial drug treat-
ment as a means of reducing deaths, disease symptoms, 
and organism-excretion time; the current drug of choice 
is ciprofloxacin (1). Of growing concern is multidrug re-
sistance, and in particular the increasing rate of resistance 
to ciprofloxacin reported for Shigella isolates from Asian 
and African regions (5). Furthermore, resistance to recom-
mended second-line antimicrobial drugs, such as the third-
generation cephalosporin ceftriaxone and the macrolide 
azithromycin, is emerging (1).
The Study
To determine antimicrobial drug resistance profiles, we 
analyzed clinical isolates representing 344 Shigella spp. 
collected during 2004–2014. We focused on molecular 
resistance mechanisms that promote resistance to currently 
recommended antimicrobial drugs.
We performed susceptibility testing by using the Kir-
by–Bauer disk-diffusion method. Results were interpreted 
according to Clinical and Laboratory Standards Institute 
performance standards (6). All 344 isolates were screened 
for plasmid-mediated quinolone resistance (PMQR) genes 
(7). A subset of 34 isolates eliciting reduced susceptibility 
to nalidixic acid, ciprofloxacin, or both, and representing 
different years of isolation was subjected to PCR-based de-
tection of mutations in the quinolone resistance-determin-
ing regions (QRDRs) of the gyrA and parC genes (7). Iso-
lates showing an extended-spectrum β-lactamase (ESBL) 
phenotype were screened by PCR for the presence of genes 
belonging to the bla
TEM
, blaSHV, and blaCTX-M families, by 
using primers described previously (8). All 344 isolates 
were analyzed for mph(A) by PCR by using previously 
published primers (9). Resulting amplicons were puri-
fied and sequenced. For database searches, we used blastn 
(http://www.ncbi.nlm.nih.gov/blast/).
Multidrug resistance was defined as resistance to >3 
classes of antimicrobial agents. Multidrug resistance was 
detected in 150 (83.8%) of the S. sonnei, 84 (78.5%) of the 
S. flexneri, 20 (60.6%) of the S. dysenteriae, and 16 (64%) 
of the S. boydii isolates (Table 1).
Resistance to nalidixic acid was detected in all species, 
but none of the S. dysenteriae and S. boydii isolates were 
resistant to ciprofloxacin (Table 1). The time distribution 
and the frequency of ciprofloxacin-resistant S. sonnei iso-
lates showed a rising tendency (Figure). A similar tendency 
was noted for ciprofloxacin-resistant S. flexneri isolates, 
which, however, revealed higher variability throughout the 
study period (Figure). No ciprofloxacin-resistant isolates 
were found before 2008. In total, 27 (15%) S. sonnei and 9 
(8.4%) S. flexneri isolates were resistant to ciprofloxacin.
The qnrS1 gene was found in 13 (3.8%) of the strains: 
4 S. dysenteriae, 4 S. flexneri, 4 S. boydii, and 1 S. sonnei. 
Other PMQR genes included qnrB19, detected in S. son-
nei (n = 1), and qnrB4, detected in combination with qepA 
in S. sonnei (n = 1). Of the 15 PMQR-positive isolates, 
only 2 were resistant to nalidixic acid and ciprofloxacin, 
illustrating the potential for development of resistance in 
susceptible strains (Table 2, http://wwwnc.cdc.gov/EID/
article/22/6/15-2088-T2.htm).
Most of the 34 isolates analyzed for mutations in their 
QRDR carried mutations in the gyrA and parC genes (Ta-
ble 2). Most frequently observed was the first-step amino 
acid substitution within GyrA at Ser83Leu (n = 14), which 
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was associated with resistance to nalidixic acid. The double 
substitutions within GyrA at Ser83Leu/Asp87Gly (n = 11) 
and Ser83Leu/Asp87Asn (n = 2) occurred invariably in 
combination with the substitution in ParC (Ser80Ille) and 
occurred in ciprofloxacin-resistant isolates. In addition, 
some unusual genotypes were detected; strains containing 
only second-step mutations within GyrA were observed 
for Asp87Tyr (n = 4) and Asp87Asn (n = 1) and were as-
sociated with resistance to nalidixic acid. The substitution 
ParC(Ala85Ser) was observed in nalidixic acid–resistant S. 
boydii isolates with Gly(Ser80Leu) (n = 2) (Table 2). 
Our data document an ongoing trend toward domi-
nance of S. sonnei, which is reflective of a current global 
shift in the epidemiologic distribution of this species (10). 
Of the 18 patients for whom travel to India was document-
ed, isolates from 55.6% were resistant to ciprofloxacin, a 
finding that supports previous reports of importation of 
ciprofloxacin-resistant Shigella from India to Europe and 
the United States (11,12) and emphasizes the need to ob-
tain travel information from patients receiving treatment 
for shigellosis. Furthermore, therapeutic efficiency of fluo-
roquinolones may be decreased because of the presence of 
PMQR determinants in phenotypically susceptible strains. 
PMQR genes are of concern because they not only pro-
mote mutations within the QRDR, resulting in resistance 
to fluoroquinolones, but they may disseminate among other 
species of Enterobacteriaceae.
Besides ciprofloxacin, the third-generation cephalo-
sporin ceftriaxone is recommended as an alternative for 
the treatment of shigellosis (1). Resistance to the broad-
spectrum β-lactam ampicillin was observed in all Shigella 
species (Table 1); however, the ESBL phenotype (resis-
tance to cefotaxime; Table 1) was restricted to S. sonnei 
and was found in 8 strains (4.5% of S. sonnei isolates). PCR 
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Table 1. Antimicrobial drug resistance of 344	Shigella spp. isolates, Switzerland,	2004–2014 
Agent 
No.	(%)	isolates 
S. sonnei,	n	=	179 S. flexneri,	n	=	107 S. dysenteriae,	n	=	33 S. boydii,	n	=	25 
Ampicllin 31	17.3) 73	(68.2) 19	(57.6) 12	(48) 
Amoxicillin/clavulanic	acid 2	(1.1) 1	(0.9) 0 0	(0) 
Cephalothin 12	(6.7) 0 0 0 
Cefotaxime 8	(4.5) 0 0 0 
Nalidixic	acid 49	(27.4) 15	(14) 2	(6) 2	(8) 
Ciprofloxacin 27	(15) 9	(8.4) 0 0  
Azithromycin* 2	(1.1) 5	(4.7) 0 0  
Trimethoprim 172	(96) 70	(65.4) 20	(60.6) 15	(60) 
Sulfamethoxazole 151	(84.4) 71	(66.4) 19	(57.6) 16	(64) 
Kanamycin	 1	(0.5) 1	(0.9) 0 0 
Gentamicin 4	(2.2) 0 0 0 
Streptomycin 163	(91) 81	(75.7) 24	(72.7) 18	(72) 
Tetracycline	 145	(81) 83	(77.6) 22	(66.6) 13	(52) 
Chloramphenicol	 6	(3.4) 56	(52.3) 9	(27.3) 2	(8) 
*For	azithromycin,	no	Clinical	and Laboratory	Standards	Institute	breakpoints for Enterobacteriaceae exist.	Isolates	harboring	mph(A) were regarded as 
resistant. 
 
Figure. Shigella spp. isolated 
in	Switzerland,	2004–2014,	and	
percentages	of	ciprofloxacin-
resistant S. sonnei and  
S. flexneri.
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analysis confirmed the presence of bla
CTX-M
 genes in all 8 
isolates: bla
CTX-M-3
 (n = 1), bla
CTX-M-14
 (n = 2), and bla
CTX-M-15
 
(n = 5) (Table 2). The establishment of bla
CTX-M
–harboring 
Shigella as an additional reservoir of these widely dissemi-
nated resistance determinants poses a threat to the treat-
ment of shigellosis, especially because all ESBLs detected 
in this study were CTX-M enzymes, which are also potent 
ceftriaxone hydrolyzers (13).
Screening of the 344 Shigella isolates for the presence 
of mph(A) revealed 7 (2%) positive strains: 2 S. sonnei and 
5 S. flexneri (Table 2). Shigella species exhibiting reduced 
susceptibility to azithromycin are of great concern because 
azithromycin, in combination with colistin, has recently 
been found to represent a potentially invaluable option for 
the treatment of gram-negative rods expressing MDR, in-
cluding carbapenem-resistant isolates of Pseudomonas ae-
ruginosa, Klebsiella pneumoniae, and Acinetobacter bau-
mannii (14). Hence, judicious use of this particular drug 
and susceptibility monitoring are warranted. Furthermore, 
our data show that mph(A) may be present in isolates dis-
playing MICs as low as 12 µg/mL, highlighting the urgen-
cy with which azithromycin susceptibility breakpoints and 
interpretive criteria for Enterobacteriaceae are needed.
Conclusions
Treatment of shigellosis with currently recommended an-
timicrobial drugs is increasingly threatened by the emer-
gence of ciprofloxacin resistance, ESBLs, or plasmid-
mediated azithromycin resistance in multidrug-resistant 
Shigella isolates. Because azithromycin is a last-resort an-
timicrobial agent used to treat shigellosis, the emergence of 
mph(A) among Shigella spp. is cause for concern.
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